This is the requisite format for presenting a poster at an event...

This is the requisite format for presenting a poster at an event such as this. Perhaps one could say that the poster should have been laminated. However, is this the extent of the criticism we can make of PAA? More to the point are the safety, efficacy and commercial opportunities for PPL-1. Specifically, what will be the results from the next cohort of human patients and separately the canines? The imminent results for both trials are the critical factors concerning the share price. In the case of humans, we are looking for confirmation of and greater extent in the reduction in the cancer marker at the higher dose. In the case of canines, we are looking for the reduction in cancer marker that has been seen in humans. The expectations are unambiguous and we should not have long to wait.